From Surf Wiki (app.surf) — the open knowledge base
3-Me-PCE
| Column 1 |
|---|
| .mw-parser-output .plainlist ol,.mw-parser-output .plainlist ul{line-height:inherit;list-style:none;margin:0;padding:0}.mw-parser-output .plainlist ol li,.mw-parser-output .plainlist ul li{margin-bottom:0} |
| DE: NpSG (Industrial and scientific use only) |
| IUPAC name |
| N-Ethyl-1-(3-methylphenyl)cyclohexanamine |
| 2201-64-1 |
| 154133693 |
| 74893746 |
| DTXSID501343119 |
| Interactive image |
| SMILES |
| CCNC1(CCCCC1)c2cc(C)ccc2 |
| InChI |
| InChI=1S/C15H23N/c1-3-16-15(10-5-4-6-11-15)14-9-7-8-13(2)12-14/h7-9,12,16H,3-6,10-11H2,1-2H3Key:USOQORZXGGZQGO-UHFFFAOYSA-N |
3-Me-PCE is the 3-methyl derivative of the internationally controlled substance Eticyclidine (PCE). It shares structural similarities with 3-MeO-PCE and 3-HO-PCE. 3-Me-PCE first appeared in the scientific literature in 2015 in the context of synthesis and analytical caracterization of a series of arylcyclohexylamines by Wallach et al. It is believed to produce ketamine-like dissociative effects predominantly via antagonism of NMDA receptors. Anecdotal evidence of its efficacy dates back to 2022 and assigns it a potency similar to other PCE analogs. The EUDA issued a notification of its first analytical identification in March 2024.
- 3-Methyl-PCP
- 3-Methyl-PCPy
- Deoxymethoxetamine
Ask Mako anything about 3-Me-PCE — get instant answers, deeper analysis, and related topics.
Research with MakoFree with your Surf account
Create a free account to save articles, ask Mako questions, and organize your research.
Sign up freeThis content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.
Report